Showing results (251-260 of 824) with videos related to
Sort By:
Pageof 83
Cancer Control : Journal of the Moffitt Cancer Center|October 29, 2003
Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancersPaul G Richardson, Teru Hideshima, Kenneth C AndersonReviews in Clinical and Experimental Hematology|February 7, 2004
Targeting proteasome inhibition in hematologic malignanciesTeru Hideshima, Paul G Richardson, Kenneth C AndersonHematology/Oncology Clinics of North America|September 13, 2014
Immunotherapy strategies in multiple myelomaJooeun Bae, Nikhil C Munshi, Kenneth C AndersonLeukemia|October 13, 2020
Changing paradigms in diagnosis and treatment of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM)Matthew Ho, Ashish Patel, Chia Yin Goh, et al.Blood|September 20, 2022
A MIR17HG-derived long noncoding RNA provides an essential chromatin scaffold for protein interaction and myeloma growthEugenio Morelli, Mariateresa Fulciniti, Mehmet K Samur, et al.Blood|March 27, 2007
JS-K, a GST-activated nitric oxide generator, induces DNA double-strand breaks, activates DNA damage response pathways, and induces apoptosis in vitro and in vivo in human multiple myeloma cellsTanyel Kiziltepe, Teru Hideshima, Kenji Ishitsuka, et al.Thescientificworldjournal|December 13, 2006
New frontiers in the treatment of multiple myelomaJanice Jin Hwang, Irene M Ghobrial, Kenneth C AndersonCancer Research|July 25, 2006
Proteasome inhibitor drugs on the riseClaudio A P Joazeiro, Kenneth C Anderson, Tony HunterClinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2022
Microenvironment Is a Key Determinant of Immune Checkpoint Inhibitor ResponseShih-Feng Cho, Kenneth C Anderson, Yu-Tzu TaiMedical Oncology (Northwood, London, England)|February 20, 2010
The evolution and impact of therapy in multiple myelomaJacob P Laubach, Paul G Richardson, Kenneth C AndersonPageof 83